Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced financial results for the fourth quarter and year ended 2019 and provided a general business update.
The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
As of late, it has definitely been a great time to be an investor Karuna Therapeutics
As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).
This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.
Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Karuna stock has nearly septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test. The drug proved itself over five weeks.
The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education
Companies in the news are: KRTX, EROS, CARO, SNNA
Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced financial results for the first quarter of 2020 and provided a general business update.
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Insiders invest in Salesforce.com, Lamb Weston, Karuna Therapeutics and Compass Diversified Holdings Continue reading...
Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a positive ...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the appointment of Christopher J. Coughlin to its board of directors. Mr. Coughlin will chair Karuna’s audit committee.
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting, to be held virtually from May 29 to May 30, 2020. The poster and oral presentation will include new and previously reported efficacy and safety data from the Phase 2 clinical trial.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics will participate in a panel presentation at Stifel’s 2nd Annual CNS Day Virtual Event on Wednesday, April 1, 2020.